Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease.

Stein AC, Rubin DT, Hanauer SB, Cohen RD. Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8.

View in: PubMed